NCT05569265

Brief Summary

MAIN AIM OF THE STUDY To establish whether hemodynamic management guided by the hypotension prediction index (HPI) guided by the administration of intravenous fluids and vasoactive drugs in patients undergoing elective major abdominal surgery reduces the incidence of postoperative moderate-severe acute kidney injury (AKI) in the 30 days after surgery. STUDY DESIGN A low intervention level clinical, blinded, controlled, randomized, multicenter, with daily follow-up of patients until hospital discharge and of postoperative complications and mortality 30 days after surgery will be performed. This is a low-intervention clinical trial comparing standard treatments:

  • The drugs used in the investigation are licensed.
  • The drugs are used according to the indications contemplated in the technical data sheet and there are published scientific data on their efficacy and safety.
  • The complementary diagnostic or follow-up procedures entail a very limited additional risk or burden to the safety of the subjects, which is minimal compared to that of standard clinical practice. STUDY DISEASE Intraoperative hemodynamic monitoring and management in surgical patients undergoing major abdominal surgery. STUDY POPULATION AND TOTAL NUMBER OF PATIENTS The sample of this study consists of patients of both genders, aged over 65 years and/or physical status ASA III or IV, undergoing elective major abdominal surgery (abdominal, urological, gynecological) under general/combined anesthesia (using laparoscopic or open approaches. To detect a 5% absolute reduction (from 10% to 5%) in the primary outcome variable (postoperative AKI up to 30 days) with a sample size ratio of 1%, and an overall type I error rate of 5%, we need 870 patients (435 per arm). Assuming a 10% loss rate, the total amounts to 958 patients, 479 for each group. DURATION OF THE STUDY The total planned duration of the overall study, which includes authorization, recruitment of subjects, and follow-up of subjects until completion of the analysis of the results obtained, is 19 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
958

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2022

Geographic Reach
1 country

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 4, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 6, 2022

Completed
2 days until next milestone

Study Start

First participant enrolled

October 8, 2022

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2024

Completed
Last Updated

March 1, 2024

Status Verified

February 1, 2024

Enrollment Period

1.3 years

First QC Date

October 4, 2022

Last Update Submit

February 29, 2024

Conditions

Keywords

Perioperative careAcute kidney injuryHemodynamic prediction indexMajor surgery

Outcome Measures

Primary Outcomes (1)

  • Acute kidney injury

    The primary outcome is the occurrence of moderate or severe AKI (according to KDIGO Stage 2-3 criteria) within 30 days after surgery. AKI is classified according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria as follows: Stage 1: Increase in serum creatinine by 1.5 to 1.9 times baseline or increase in serum creatinine by 0.3 mg/dL, or reduction in urine output to \<0.5 mL/kg/hour for 6 to 12 hours. Stage 2: Increase in serum creatinine by 2.0 to 2.9 times baseline, or reduction in urine output to \<0.5 mL/kg/hour for \>12 hours. Stage 3: Increase in serum creatinine to 3.0 times baseline, or increase in serum creatinine to \>4.0 mg/dL or reduction in urine output to \<0.3 mL/kg/hour for \>24 hours, or anuria for \>12 hours, or initiation of renal replacement therapy, or, in patients \<18 years, decrease in estimated glomerular filtration rate (eGFR) to \<35 mL/min/1.73 m2.

    7 days after surgery

Secondary Outcomes (7)

  • Need for renal replacement therapy (RRT)

    30 days after surgery

  • renal replacement therapy (RRT) duration

    30 days after surgery

  • Renal recovery on day 30

    30 days after surgery

  • Mortality

    30 days after surgery

  • Postoperative complications

    30 days after surgery

  • +2 more secondary outcomes

Study Arms (2)

Hemodynamic prediction index based goal directed hemodynamic therapy

EXPERIMENTAL

Hemodynamic handling will be based hemodynamic prediction index (HPI)

Procedure: Intraoperative hemodynamic management

No HPI

NO INTERVENTION

Patients in the control group will be treated according to standard practice.

Interventions

Goal directed Hemodynamic therapy

Also known as: Fluid therapy
Hemodynamic prediction index based goal directed hemodynamic therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients over 65 years of age and/or physical condition ASA III or IV.
  • Patients who have major elective abdominal surgery indicated: general surgery, urology, gynecology, by laparoscopic or open approaches.
  • Patients who sign the informed consent, agreeing to participate in the study.

You may not qualify if:

  • Stage 4 or 5 chronic kidney disease (eGFR \< 15 ml/ min)
  • Renal transplantation in the previous 12 months
  • Glomerulonephritis, interstitial nephritis or vasculitis
  • Pre-existing AKI
  • Renal replacement therapy (RRT) in the last 90 days
  • Participation in another interventional trial investigating a drug/intervention affecting renal function
  • Patients with atrial fibrillation
  • Patients with known cardiac shunts.
  • Patients whose surgical indication is urgent
  • Pregnancy or lactation
  • Patients expected to die within 30 days.
  • Acute myocardial ischemia within the previous 30 days.
  • Acute pulmonary edema within the previous 30 days
  • Any contraindication to vasoactive or inotropic medication at low doses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Hospital Universitario Bellvitge

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

Location

Hospital Universitario de Badajoz

Badajoz, Spain

Location

Hospital Clínic de Barcelona

Barcelona, Spain

Location

Hospital del Mar

Barcelona, Spain

Location

Hospital Universitario de Sant Pau

Barcelona, Spain

Location

Hospital Universitario Moises Brogi

Barcelona, Spain

Location

Hospital Uniuversitario de Basurto

Bilbao, Spain

Location

Hospital Universitario Reina Sofía

Córdoba, Spain

Location

Hospital Universitario Doctor Trueta

Girona, Spain

Location

Hospital San Cecilio

Granada, Spain

Location

Hospital Universitario Virgen de Las Nieves

Granada, Spain

Location

Hospital Universitario Juan Ramón Jimenez

Huelva, Spain

Location

Hospital Universitario de Igualada

Igualada, Spain

Location

Hospital Universitario Jerez de la Frontera

Jerez de la Frontera, Spain

Location

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, Spain

Location

Hospital Infanta Leonor

Madrid, Spain

Location

Hospital Universitario Ramón y Cajal

Madrid, Spain

Location

Hospital Universitario Puerta de Hierro

Majadahonda, Spain

Location

Althai Xarxa Universitaria

Manresa, Spain

Location

Hospital Universitario de Donostia

San Sebastián, Spain

Location

Hospital Universitario Marqués de Valdecilla

Santander, Spain

Location

Hospital Clínico Universitario de Santiago

Santiago de Compostela, Spain

Location

Hospital Universitario Virgen de la Macaarena

Seville, Spain

Location

Hospital Universitario Virgen del Rocío

Seville, Spain

Location

Hospital General Universitario de Valencia

Valencia, Spain

Location

Hospital Universitario Ríio Hortega

Valladolid, Spain

Location

Related Publications (3)

  • Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.

    PMID: 23835589BACKGROUND
  • Wijnberge M, Geerts BF, Hol L, Lemmers N, Mulder MP, Berge P, Schenk J, Terwindt LE, Hollmann MW, Vlaar AP, Veelo DP. Effect of a Machine Learning-Derived Early Warning System for Intraoperative Hypotension vs Standard Care on Depth and Duration of Intraoperative Hypotension During Elective Noncardiac Surgery: The HYPE Randomized Clinical Trial. JAMA. 2020 Mar 17;323(11):1052-1060. doi: 10.1001/jama.2020.0592.

    PMID: 32065827BACKGROUND
  • Ripolles-Melchor J, Carrasco-Sanchez L, Tome-Roca JL, Aldecoa C, Zorrilla-Vaca A, Lorente-Olazabal JV, Colomina MJ, Perez A, Jimenez-Lopez JI, Navarro-Perez R, Abad-Gurumeta A, Monge-Garcia MI; HYT Study Group. Hypotension prediction index guided goal-directed therapy to reduce postoperative acute kidney injury during major abdominal surgery: study protocol for a multicenter randomized controlled clinical trial. Trials. 2024 Apr 29;25(1):288. doi: 10.1186/s13063-024-08113-w.

MeSH Terms

Conditions

Postoperative ComplicationsAcute Kidney Injury

Interventions

Fluid Therapy

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Drug TherapyTherapeutics

Study Officials

  • Javier Ripollés Melchor, MD

    Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

October 4, 2022

First Posted

October 6, 2022

Study Start

October 8, 2022

Primary Completion

January 15, 2024

Study Completion

February 25, 2024

Last Updated

March 1, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will share

Upon specific request following the publication of the study

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
From publication on clinicaltrials.org until 1 year after publication of the results.
Access Criteria
under request and Steering Committe review

Locations